Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

Parameter Non-responders Responders P value DAS28 > 3.2 (week 24) DAS28 ≤ 3.2 (week 24) P value
(n = 11) (n = 33) (n = 29) (n = 15)
Age in years (mean ± SD) 58.9 ± 10.8 62.5 ± 13.3 0.423 61.8 ± 13.8 61.3 ± 10.7 0.898
Female gender, % 72 81 0.640 76 87 0.411
Disease duration in years (mean ± SD) 15.1 ± 12.7 12.9 ± 8.8 0.536 12.7 ± 10.5 15.4 ± 8.1 0.428
DAS28-ESR (mean ± SD) 5.0 ± 1.1 6.0 ± 1.1 0.008 5.8 ± 1.1 5.7 ± 1.3 0.753
RF-positive, % 100 87 0.236 86 100 0.138
ACPA-positive, % 78 76 0.909 72 85 0.399
Corticosteroids, % 36 30 0.061 34 26 0.608
Previous TNF inhibitors (mean ± SD) 1.7 ± 1.2 1.2 ± 0.9 0.194 1.5 ± 1.1 1.2 ± 0.7 0.346
  1. Significant P values are indicated in bold numbers
  2. DAS28 disease activity score in 28 joints, SD standard deviation, ESR erythrocyte sedimentation rate, RF rheumatoid factor IgM, ACPA anti-citrullinated peptide antibody, TNF tumor necrosis factor